Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion

BACKGROUND: Although rare, NTRK gene fusions are known to be oncogenic drivers in pancreatic ductal adenocarcinoma (PDAC). We report the response of a metastatic CTRC-NTRK1 gene fusion-positive PDAC to targeted treatment with the oral tropomyosin receptor kinase (TRK) inhibitor larotrectinib and the...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Reilly, E M, Hechtman, J F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859823/
https://www.ncbi.nlm.nih.gov/pubmed/31605106
http://dx.doi.org/10.1093/annonc/mdz385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859823/
https://www.ncbi.nlm.nih.gov/pubmed/31605106
http://dx.doi.org/10.1093/annonc/mdz385

Ejemplares similares